


**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**


Claim 36 (new): A compound represented by general formula (I):



(I)

wherein R<sub>1</sub> represents hydroxyl and R<sub>2</sub> represents methoxy.


Claim 37 (new): A compound represented by general formula (II):



(II)

wherein R<sub>3</sub> represents hydroxyl and R<sub>4</sub> represents methoxy.

Claim 38 (new): A compound represented by general formula (III):



(III)

wherein 3-hydroxyl in 3-hydroxy-1-butenyl is in a 3S configuration.

Claim 39 (new): A carcinostatic agent, comprising as an active ingredient a compound according to claim 36.

Claim 40 (new): The carcinostatic agent according to claim 39, for use in the treatment of animal or human cancer.


Claim 41 (new): The carcinostatic agent according to claim 40, wherein said cancer is leukemia.

Claim 42 (new): The carcinostatic agent according to claim 41, wherein said leukemia is acute myelogenous leukemia.

Claim 43 (new): An anti-acute myelogenous leukemia agent, comprising as an active ingredient at least one compound selected from the group consisting of a compound represented by formula (I), wherein R<sub>1</sub> and R<sub>2</sub> represent hydroxyl, a compound represented by formula (I), wherein R<sub>1</sub> represents a hydrogen atom and R<sub>2</sub> represents hydroxyl, a compound represented by formula (I), wherein R<sub>1</sub> represents a hydrogen atom and R<sub>2</sub> represents methoxy,

a compound represented by formula (II), wherein R<sub>3</sub> and R<sub>4</sub> represent methoxy, a compound represented by formula (II), wherein R<sub>3</sub> represents methoxy and R<sub>4</sub> represents hydroxyl,


a compound represented by general formula (IV),



(IV)

, and

a compound represented by general formula (V),



(V)

Claim 44 (new): The anti-acute myelogenous leukemia agent according to claim 43, for use in the treatment of animal or human acute myeloid leukemia.

Claim 45 (new): A process for producing a composition comprising the steps of:

providing a raw material comprising the compounds of claims 36 to 38 and 43;  
extracting said raw material with a solvent;  
supplying said extract to an ion-exchange chromatograph wherein said extract is subjected to solvent extraction with a first lower alcohol, a second lower alcohol, and optionally a lower ester in that order,  
whereby a composition comprising each of said compounds is provided in a fraction of said second lower alcohol.

Claim 46 (new): The process according to claim 45, wherein said raw material is a plant belonging to the family Compositae or a plant belonging to the genus Ludwigia of the family Onagraceae.

Claim 47 (new): A process for obtaining compounds comprising the steps of:

providing a composition comprising the compounds of claims 36 to 38 and 43; and repeating the separation of said composition by chromatography a plurality of times to obtain said compounds.

Claim 48 (new): The process according to claim 47, wherein said composition has been produced by the process according to claim 45.

Claim 49 (new): A process for separating a composition containing compounds according to claims 36 to 38 and 43 into a first composition and a second composition, said process comprising:

providing a composition comprising said compounds; and separating said composition by normal phase chromatography and then by reverse phase chromatography into a first composition and a second composition,

said first composition comprising compounds according to claims 36 to 38, a compound represented by general formula (I), wherein R<sub>1</sub> and R<sub>2</sub> represent hydroxyl, a compound represented by general formula (IV), and a compound represented by general formula (V),

said second composition comprising a compound represented by general formula (I), wherein R<sub>1</sub> represents a hydrogen atom and R<sub>2</sub> represents hydroxyl and a compound represented by general formula (I), wherein R<sub>1</sub> represents a hydrogen atom and R<sub>2</sub> represents methoxy.

Claim 50 (new): The process according to claim 49, wherein said composition has been produced by the process according to claim 45.

Claim 51 (new): A process for producing compounds comprising the steps of:

providing a composition comprising the compounds of claims 36 to 38, a compound represented by general formula (I), wherein R<sub>1</sub> and R<sub>2</sub> represent hydroxyl, a compound represented by general formula (IV), and a compound represented by general formula (V); and

separating said composition by at least one of normal phase chromatography, reverse phase chromatography, liquid chromatography, or a combination thereof to isolate said compounds.

Claim 52 (new): The process according to claim 51, wherein said composition is a first composition produced by the process according to claim 49.

Claim 53 (new): A process for producing compounds comprising the steps of:

providing a composition comprising compounds represented by general formula (I), wherein R<sub>1</sub> represents a hydrogen atom and R<sub>2</sub> represents hydroxyl and a

compound represented by general formula (I), wherein R<sub>1</sub> represents a hydrogen atom and R<sub>2</sub> represents methoxy; and

separating said composition by at least one of normal phase chromatography, reverse phase chromatography, or a combination thereof to isolate said compounds.

Claim 54 (new): The process according to claim 53, wherein said composition is a second composition produced by a process according to claim 49.

Claim 55 (new): A compound according to claim 36, wherein said compound is produced by a process according to claim 47.


Claim 56 (new): An anti-ovarian cancer agent, comprising as an active ingredient a compound represented by general formula (II), wherein R<sub>3</sub> and R<sub>4</sub> represent methoxy.

Claim 57 (new): The anti-ovarian cancer agent according to claim 56 for use in the treatment of an animal or human ovarian cancer.


Claim 58 (new): An anti-prostatic cancer agent, comprising as an active ingredient a compound represented by general formula (II), wherein R<sub>3</sub> and R<sub>4</sub> represent methoxy.

Claim 59 (new): The anti-prostatic cancer agent according to claim 56, for use in the treatment of an animal or human prostatic cancer.

Claim 60 (new): A process for producing a composition comprising a compound represented by general formula (VI):




a compound represented by general formula (VII):



(VII)


a compound represented by general formula (VIII):



(VIII)

, and

a compound represented by general formula (IX):



(IX)

‘  
said process comprising the steps of:  
providing a raw material comprising said compounds;  
extracting said raw material with a solvent; and  
supplying said extract to an ion-exchange chromatograph wherein said extract  
is subjected to solvent extraction with a first lower alcohol, a second lower alcohol, and  
optionally a lower ester in that order,  
whereby a composition comprising said compounds is provided in a fraction of  
said second lower alcohol.

Claim 61 (new): The process according to claim 60, wherein said raw material is a plant belonging to the family Compositae or a plant belonging to the genus Ludwigia of the family Onagraceae.

Claim 62 (new): A process for obtaining compounds represented by general formulae (VI) to (IX), comprising the steps of:  
providing a composition comprising said compounds; and  
repeating the separation of said composition by chromatography a plurality of times to obtain said compounds.

Claim 63 (new): The process according to claim 62, wherein said composition has been produced by the process according to claim 60.

Claim 64 (new): A process for separating a composition comprising compounds represented by general formulae (VI) to (IX) into a third composition and a fourth composition, said process comprising the steps of:  
providing a composition comprising said compounds; and  
separating said composition by normal phase chromatography and then by reverse phase chromatography into a third composition and a fourth composition,  
said third composition comprising a compound represented by general formula (VI) and a compound represented by general formula (IX),  
said fourth composition comprising a compound represented by general formula (VII) and a compound represented by general formula (VIII).

Claim 65 (new): The process according to claim 64, wherein said composition has been produced by the process according to claim 60.

Claim 66 (new): A process for producing a compound represented by general formula (VI) and a compound represented by general formula (IX), said process comprising the steps of:

providing a composition comprising said compounds; and  
separating said composition by at least one of normal phase chromatography, reverse phase chromatography, liquid chromatography, or a combination thereof to isolate said compounds.

Claim 67 (new): The process according to claim 66, wherein said composition is a third composition produced by the process according to claim 64.

Claim 68 (new): A process for producing a compound represented by general formula (VII) and a compound represented by general formula (VIII), said process comprising the steps of:

providing a composition comprising said compounds; and  
separating said composition by at least one of normal phase chromatography, reverse phase chromatography, liquid chromatography, or a combination thereof to isolate said compounds.

Claim 69 (new): The process according to claim 68, wherein said composition is a fourth composition produced by a process according to claim 64.

Claim 70 (new): Compounds represented by general formulae (VI) to (IX), produced by a process according to claim 62.